Cost of UK’s drug price with US will come out of NHS budget

The UK government's drug pricing deal with the Trump administration will result in increased costs that will be borne by the National Health Service (NHS) budget, rather than the Treasury. The initial additional cost is estimated to be £1 billion over three years, but campaigners fear this could eventually reach £9 billion per year. The Department of Health and Social Care, which funds the NHS in England, will be responsible for covering these costs, rather than the Treasury. This means that the resources available for the NHS may be diverted to accommodate the increased drug prices, potentially impacting the quality and accessibility of healthcare services. The article highlights the concerns of campaigners regarding the financial implications of this deal, which they believe could have significant consequences for the NHS and the overall healthcare system in the UK.